Similar articles

• Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.

  Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Hille DA, Nieminen MS, Edelman JM, Devereux RB. Okin PM, et al. Circ Arrhythm Electrophysiol. 2008 Dec;1(5):337-43. doi: 10.1161/CIRCEP.108.795351. Epub 2008 Dec 2. Circ Arrhythm Electrophysiol. 2008. PMID: 19808428 Clinical Trial.
• Slower heart rates for healthy hearts: time to redefine tachycardia?

  Gopinathannair R, Sullivan RM, Olshansky B. Gopinathannair R, et al. Circ Arrhythm Electrophysiol. 2008 Dec;1(5):321-3. doi: 10.1161/CIRCEP.108.835264. Circ Arrhythm Electrophysiol. 2008. PMID: 19808425 No abstract available.
• [Hypertension and the heart].

  Wachtell K, Andersen NH, Svendsen TL. Wachtell K, et al. Ugeskr Laeger. 2009 Jun 15;171(25):2113-6. Ugeskr Laeger. 2009. PMID: 19671394 Danish.
• Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.

  Devereux RB, Dahlöf B. Devereux RB, et al. Curr Med Res Opin. 2007 Feb;23(2):443-57. doi: 10.1185/030079906X167435. Curr Med Res Opin. 2007. PMID: 17288698 Review.
• Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.

  Makkar KM, Sanoski CA, Spinler SA. Makkar KM, et al. Pharmacotherapy. 2009 Jan;29(1):31-48. doi: 10.1592/phco.29.1.31. Pharmacotherapy. 2009. PMID: 19113795 Review.